-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FJMMyectsQCSHvANw1f2Ver3PDSNRXQ63ZDUxwetgIypsE06kOIl16zfYBhKKSXM
 c5EDofF8dZRJzpItN6VtRg==

<SEC-DOCUMENT>0001104659-09-057916.txt : 20091006
<SEC-HEADER>0001104659-09-057916.hdr.sgml : 20091006
<ACCEPTANCE-DATETIME>20091006124749
ACCESSION NUMBER:		0001104659-09-057916
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20091001
FILED AS OF DATE:		20091006
DATE AS OF CHANGE:		20091006

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			SHANNON TIMOTHY M
		CENTRAL INDEX KEY:			0001207114

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		091107547

	MAIL ADDRESS:	
		STREET 1:		C/O CURAGEN CORP
		STREET 2:		555LONG WHARF DR. 11TH FL.
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>a3.xml
<DESCRIPTION>3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0203</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2009-10-01</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000744218</issuerCik>
        <issuerName>Celldex Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CLDX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001207114</rptOwnerCik>
            <rptOwnerName>SHANNON TIMOTHY M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CELLDEX THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>119 FOURTH AVENUE</rptOwnerStreet2>
            <rptOwnerCity>NEEDHAM</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02494</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock, par value $.001 per share</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>66212</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to purchase)</value>
                <footnoteId id="F2"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.48</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2009-10-01</value>
            </exerciseDate>
            <expirationDate>
                <value>2019-01-20</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $.001 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>155986</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to purchase)</value>
                <footnoteId id="F3"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.89</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2009-10-01</value>
            </exerciseDate>
            <expirationDate>
                <value>2017-09-25</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $.001 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>68475</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to purchase)</value>
                <footnoteId id="F4"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.89</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2009-10-01</value>
            </exerciseDate>
            <expirationDate>
                <value>2017-09-25</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $.001 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>68475</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Received in exchange for 241,740 shares of CuraGen, Corp. (&quot;CuraGen&quot;) common stock, at an exchange ratio of .2739, in connection with the merger of CuraGen with and into Cottrell Merger Sub, Inc., a direct wholly-owned subsidiary of Celldex Therapeutics, Inc. (the &quot;Merger&quot;).</footnote>
        <footnote id="F2">Received in the Merger in exchange for a stock option to acquire 569,500 shares of CuraGen common stock for $.68 per share.</footnote>
        <footnote id="F3">Received in the Merger in exchange for a stock option to acquire 250,000 shares of CuraGen common stock for $1.34 per share.</footnote>
        <footnote id="F4">Received in the Merger in exchange for a stock option to acquire 250,000 shares of CuraGen common stock for $1.34 per share</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Timothy Shannon</signatureName>
        <signatureDate>2009-10-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----